Adcetris-Chemotherapy Combo Lengthens the Time for Hodgkin’s Lymphoma to Progress, Trial Shows
News
Adding Adcetris (brentuximab vedotin) to standard chemotherapy significantly lengthens the time it takes for Hodgkin’s lymphoma to progress, or for a patient to die, according to an updated of Phase 3 clinical ... Read more
Tazemetostat Benefits Follicular and B-cell Lymphoma Patients with EZH2 Mutations, Phase 2 Trial Shows
News
Twelve of 13 patients with relapsed or refractory follicular lymphoma (FL) and mutations of the EZH2 enzyme responded either fully or partially to treatment with tazemetostat, according to a Phase 2 clinical trial. Tazemetostat, ... Read more
FDA Approves Rituxan Hycela to Treat Two Lymphomas and One Type of Leukemia
News
Rituxan Hycela has received U.S. Food and Drug Administration approval as an injected treatment for two lymphomas and a type of leukemia, Genentech announced. The approval covers Rituxan Hycela’s use against relapsed or ... Read more
10 Ways Exercise Is Beneficial When Going Through Cancer Treatment
ADC Reports Positive Phase 1 Results on Antibody-drug Conjugate ADCT-301 for Hodgkin’s, NHL
News
Preliminary results from a Phase 1 trial testing ADC Therapeutics’ ADCT-301 to treat relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma (NHL) demonstrated the medication’s therapeutic potential with good overall response rates and low ... Read more
Truxima Shows Similar Safety and Efficacy Results to Rituxan in Phase 3 Trial
News
Results from a Phase 3 trial have shown that Truxima (CT-P10), developed by Celltrion Healthcare, has a similar efficacy and safety profile as Genetech’s Rituxan (rituximab) for the treatment of advanced-stage follicular lymphoma. ... Read more
Hodgkin’s Lymphoma: The ‘Good’ Cancer?
Overcoming Adversity- a Column by Radiant Racheli
Following my Hodgkin’s lymphoma (HL) diagnosis, I encountered a plethora of people who responded with “Oh! But that’s the GOOD cancer, right?” After my initial diagnosis my general practitioner under-prepared me for the ... Read more
The Lymphoma Association Explains What Lymphoma Is
How Essential Oils Can Benefit Chronic Illness Sufferers
At Least Four-fifths of Leukemia and Lymphoma Patients Respond to TRG-1202 Combo Therapy, Researchers Report
News
Ninety-four percent of patients with chronic lymphocytic leukemia and 79 percent with mantle cell lymphoma responded to treatment with a combination of TGR-1202 (umbralisib), Imbruvica (ibrutinib), and TG-1101, according to updated Phase ... Read more
Seattle Genetics Asks FDA to Approve Adcetris for Expanded Set of Lymphoma Patients
News
Seattle Genetics is asking the U.S. Food and Drug Administration to approve Adcetris (brentuximab vedotin) for an expanded set of cutaneous T-cell lymphoma patients. The agency has yet to authorize Adcetris for CTCL. A supplemental Biologics ... Read more